For instance, engagers targeting NK cells for CD30+ lymphoma, CD133+ colon cancer, CD33+ myelodysplastic syndrome, CLEC12A+ and CD33+ acute myeloid cell (AML) are all in clinical development. Here, CD33 is linked to lymphoma.